Ignyta’s RXDX-106 Works with Immune Checkpoint Inhibitors to Kill Tumors, Study Shows – Immuno-Oncology News
Immuno-Oncology News |
Ignyta's RXDX-106 Works with Immune Checkpoint Inhibitors to Kill Tumors, Study Shows
Immuno-Oncology News Ignyta's RXDX-106 can restore the body's immune-system response against several types of tumors and work with immune checkpoint inhibitors to kill tumor cells, according to a company presentation at the American Association for Cancer Research annual … |
